Menu
Subscribe to our Email Alerts
Home
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Amplia's Pipeline
Cancer Program
Fibrosis Program
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements and Reports
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Announcements and Reports
Home
>
Announcements and Reports
>
ASX Announcements
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
30-May-2022
Preliminary Final Report and Annual Report YE 31 March 2022
13-May-2022
Amplia Receives Second Ethics Clearance for Phase 2 Trial
12-May-2022
Amplia Presentation to 16th Bioshares Biotech Summit
9-May-2022
AMP945 Pre-IND Meeting Outcome
19-Apr-2022
Quarterly Activities and Cashflow Reports - March 2022 Qtr
6-Apr-2022
Ethics Clearance Phase 2 Trial - Pancreatic Cancer Patients
5-Apr-2022
Notification of cessation of securities - ATX
17-Feb-2022
AMP945 Improves Survival in Human Pancreatic Cancer Model
15-Feb-2022
ATX Abstract accepted for presentation at Cancer Conference
14-Feb-2022
Sale of Unmarketable Parcels of Shares
Previous
1
2
3
4
5
6
Next
